作者:Li-Qiang Han、Xia Yuan、Xing-Yu Wu、Ri-Dong Li、Bo Xu、Qing Cheng、Zhen-Ming Liu、Tian-Yan Zhou、Hao-Yun An、Xin Wang、Tie-Ming Cheng、Ze-Mei Ge、Jing-Rong Cui、Run-Tao Li
DOI:10.1016/j.ejmech.2016.10.023
日期:2017.1
A novel class of urea-containing peptide boronic acids as proteasome inhibitors was designed by introducing a urea scaffold to replace an amido bond. Compounds were synthesized and their antitumor activities were evaluated. After two rounds of optimizations, the compound I-14 was found to be a potent proteasome inhibitor. Compared with Bortezomib, I-14 showed higher potency against the chymotrypsin-like
通过引入尿素支架取代酰胺键,设计了一类新型的含尿素的肽硼酸作为蛋白酶体抑制剂。合成化合物并评估其抗肿瘤活性。经过两轮优化后,发现化合物I-14是有效的蛋白酶体抑制剂。与Bortezomib相比,I-14对人20S蛋白酶体的胰凝乳蛋白酶样活性具有更高的效力(IC 50 <1 pM),对四种不同癌细胞系具有相似的效力(IC 50 <10 nM),并且具有更好的药代动力学特征。此外,I-14在Bel7404小鼠异种移植模型中显着抑制了肿瘤的生长。I-14对蛋白酶体的优异抑制作用 通过对接和分子动力学研究进行了合理化。